Home › Research › Tau biomarkers
Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease
Panagiotis Alexopoulos, Lukas Werle, Jennifer Roesler, Nathalie Thierjung, Lena Sophie Gleixner, Igor Yakushev, Nikolaos Laskaris, Stefan Wagenpfeil et al.. Alzheimer's research & therapy, 2016-12-09
Topic: Plasma and spinal-fluid biomarkers
Patients with all biomarkers positive for AD (N = 145) had the highest hazard for progression to dementia due to AD, whilst patients with no positive biomarkers (N = 111) had the lowest. The risk of patients with only abnormal p-Tau and/or t-Tau (N = 49) or with positive Aβ42 in combination with positive t-Tau or p-Tau (N = 119) is significantly lower than that of patients with all biomarkers positive. The risk of progression to dementia due to AD differs between patients with different CSF biomarker constellations.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Alexopoulos, P., Werle, L., Roesler, J., Thierjung, N., Gleixner, L. S., Yakushev, I., et al. (2016). Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-016-0220-z
Vancouver
Alexopoulos P, Werle L, Roesler J, Thierjung N, Gleixner LS, Yakushev I, et al. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease. Alzheimer's research & therapy. 2016. doi:10.1186/s13195-016-0220-z. PMID: 27931251.
BibTeX
@article{alexopoulos2016-27931251,
author = {Alexopoulos, Panagiotis and Werle, Lukas and Roesler, Jennifer and Thierjung, Nathalie and Gleixner, Lena Sophie and Yakushev, Igor and Laskaris, Nikolaos and Wagenpfeil, Stefan and others},
title = {{Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease}},
journal = {Alzheimer's research \& therapy},
year = {2016},
doi = {10.1186/s13195-016-0220-z},
pmid = {27931251},
url = {https://doi.org/10.1186/s13195-016-0220-z}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Patients with all biomarkers positive for AD (N = 145) had the highest hazard for progression to dementia due to AD, whilst patients with no positive biomarkers (N = 111) had the lowest.
- The risk of patients with only abnormal p-Tau and/or t-Tau (N = 49) or with positive Aβ42 in combination with positive t-Tau or p-Tau (N = 119) is significantly lower than that of patients with all biomarkers positive.
- The risk of progression to dementia due to AD differs between patients with different CSF biomarker constellations.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants145
- Evidence strengthModerate
How this study scored 51/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and free to read, so those were left out: it earned 30 of the 59 points we could judge it on, which is 51 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 145 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27931251) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 30 / 59 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 30 of the 59 points we could judge it on is 51 out of 100. |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers
Also tagged “neurofilament”
693 studies in the library carry the topic tag “neurofilament”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 693 tagged studies.